Novavax Launches Phase 3 Trial of Its COVID-19 Vaccine in US

To date, two COVID-19 vaccines have been accepted in the US: one developed by Pfizer and BioNTech, and one other made by Moderna. Both of these vaccines use messenger RNA (mRNA) to show cells methods to make a protein that triggers an immune response to COVID-19.

American firm Novavax on Monday introduced that it has launched a part 3 trial of its COVID-19 vaccine, making it the fifth firm to begin a late-stage vaccine trial in the US.

The trial, which is being partly funded by the US National Institute of Allergy and Infectious Diseases (NIAID), will decide the protection and efficacy of NVX-CoV2373, the vaccine candidate developed by Novavax.

“Addressing the unprecedented health crisis of COVID-19 has required extraordinary efforts on the part of government, academia, industry and the community,” mentioned NIAID Director Anthony Fauci in the information launch. “The launch of this study — the fifth investigational COVID-19 vaccine candidate to be tested in a phase 3 trial in the United States — demonstrates our resolve to end the pandemic through development of multiple safe and effective vaccines.”

Study volunteers will obtain two injections of the vaccine, with the second shot administered 21 days after the primary.

Novavax’s vaccine is constructed from a stabilized type of the spike protein of SARS-CoV-2, the virus that causes COVID-19, utilizing the corporate’s recombinant protein nanoparticle expertise. The spike protein permits the virus to penetrate host cells and trigger an infection. Recombinant proteins are proteins containing genetic materials from a number of sources.

In earlier trials on animals, injection of NVX-CoV2373 generated antibodies that blocked the COVID-19 spike protein from binding to the cell floor receptors the virus focused.

The US Food and Drug Administration (FDA) approved emergency use of the Pfizer and Modern vaccines earlier this month.

Vaccine makers AstraZeneca and Johnson & Johnson are additionally anticipated to launch security and efficacy knowledge from late-stage trials as early as January. 

Early knowledge launched in November confirmed that the AstraZeneca vaccine was solely 62% efficient in comparison with these of Pfizer and Moderna, which have 95% and 94% efficacy, respectively.

“We think we have figured out the winning formula and how to get efficacy that, after two doses, is up there with everybody else,” Soriot mentioned.

Early outcomes have indicated {that a} single dose of the Johnson & Johnson vaccine led to COVID-19 antibodies being detected in 97% of individuals. Additional knowledge on the vaccine’s effectiveness in a scientific setting is predicted in early 2021.


Related posts